MP29-02: A breakthrough for the treatment of allergic rhinitis

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 15, 2013, Pages 2101-2113

  Bernstein, Jonathan A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Allergic rhinitis; Dymista; MP29 02; Unmet medical need

Indexed keywords

ANTIALLERGIC AGENT; AZELASTINE; AZELASTINE PLUS FLUTICASONE PROPIONATE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; MP 2902; PLACEBO; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; AUTUMN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; HAY FEVER; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NOSE OBSTRUCTION; PRICK TEST; REVIEW; RHINORRHEA; SEASON; SNEEZING; SPRING; SUMMER; SYMPTOM;

ADRENAL CORTEX HORMONES; ANDROSTADIENES; DRUG COMBINATIONS; HUMANS; PHTHALAZINES; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 84884567374     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.828693     Document Type: Review

References (37)

1. Canonica GW, Bousquet J, Mullol J, et al. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(Suppl 85):17-25
2. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 2007;62(Suppl 85):9-16
3. Bernstein JA, Levin LS, Al-Shuik E, et al. Clinical characteristics of chronic rhinitis patients with high vs low irritant trigger burdens. Ann Allergy Asthma Immunol 2012;109:173-8
4. Bernstein JA. Allergic and mixed rhinitis: epidemiology and natural history. Allergy Asthma Proc 2010;31:365-9
5. Mosges R, Klimek L. Today's allergic rhinitis patients are different: new factors that may play a role. Allergy 2007;62:969-75
6. Bousquet J, Bachert C, Canonica GW, et al. Extended Global Allergy and Asthma European Network, World Allergy Organization and Allergic Rhinitis and its Impact on Asthma Study Group. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol 2009;124:428-33
7. Bousquet PJ, Bachert C, Canonica GW, et al. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol 2010;126:666-8
8. Hellings PW, Fokkens WJ, Akdis C, et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013;68:1-7
9. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its Impact on Asthma (ARIA) 2008 update (In collaboration with the World Health Organization, GA(2)LEN and AllerGen. Allergy 2008;63(Suppl 86):8-160
10. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Global Allergy and Asthma European Network; Grading of Recommendations Assessment, Development and Evaluation Working Group. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76
11. Wallace DV, Dykewicz MS, Bernstein DI, et al. Joint Tast Force on Practice; American Academy of Allergy Asthma & Immunology; American College of Allergy Asthma & Immunology; Joint Council of Allergy Asthma & Immunol. The diagnosis and management of rhinitis; an updated practice parameter. J Allergy Clin Immunol 2008;122(2 Suppl):S1-84
12. Bousquet PJ, Demoly P, Devillier P, et al. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol 2013;160:393-400
13. Pitman R, Paracha N, Parker C, et al. Episode pattern and healthcare utilisation in patients with seasonal allergic rhinitis. Presented at EAACI; 16-20 June 2012; Geneva
14. Demoly P, Allaert FA, Lecasble M. PrAGMA. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy 2002;57:546-54
15. Dalal AA, Standrod R, Henry H, et al. Economic burden of rhinitis in managed care: a retrospective claims data analysis. Ann Allergy Asthma Immunol 2008;101:23-9
16. Mullol J. A survey of the burden of allergic rhinitis in Spain. J Investig Allergol Clin Immunol 2009;19:27-34
17. Price D, Bousquet J, Pitman R, et al. Sub-optimal control of allergic rhinitis the need for a new and more effective treatment option. Presented at EAACI; 22-26 June 2013; Milan
18. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007;28(1):3-9
19. Meltzer EO, Gross GN, Katial R, et al. Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations. J Fam Pract 2012;61(2 Suppl):S5-10
20. Meltzer E, Ratner P, Bachert C, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol 2013;161(4):369-77
21. Derendorf H, Munzel U, Petzold U, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol 2012;74:125-33
22. EMA guideline: guideline on the Clinical Development of Medicinal Products for the Treatment of Allergic Rhinoconjunctivitis. CHMP/EWP/2455
23. 2004.Available from: http://www. ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003554.pdf [Accessed 29 April 2013]
24. FDA Draft Guidance or Industry Patient-Reported Outcome Measures: use in Medical Product Development to Support Labeling Claims. 2009. Available from: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/UCM193282.pdf [Accessed 29 April 2013]
25. Hampel FC, Ratner PH, Van bavel J, et al. Double-blind placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010;105:168-73
26. Carr W, Bernstein J, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282-9
27. Meltzer EO, LaForce C, Ratner P, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc 2012;33:324-32
28. Price D, Bousquet J, Hellings P, et al. Short-and long-term safety of MP29-02: a new therapy for the treatment of allergic rhinitis. Presented at SERIN; 21-23 March 2013; Leuven
29. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83
30. International Committee on Harmonization Harmonized Tripartite Guidelines on Good Clinical Practice. 1996. Available from: http://www.ich. org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/ E6-R1-Guideline.pdf [Accessed 17 June 2011]
31. Price D, Shah S, Hatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 2013; In press
32. Meltzer EO, Orgel HA, Bronsky EH, et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms rhinomanometry, and nasal cytology. J Allergy Clin Immunol 1990;86:221-30
33. Van As A, Bronsky E, Grossman J, et al. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy 1991;67:156-62
34. Nathan RA, Bronsky EA, Fireman P, et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 1991;67:332-8
35. Tomooka LT, Murphy C, Davidson TM. Clinical study and literature review of nasal irrigation. Laryngoscope 2000;110:1189-93
36. Cordray S, Harjo JB, Miner L. Comparison of intranasal hypertonic Dead Sea saline spray and intranasal aqueous triamcinolone spray in seasonal allergic rhinitis. Ear Nose Throat J 2005;84:426-30
37. Leung DYM, Szefler SJ. The Editor's Choice. MP29-02: a major advancement in the treatment of Allergic rhinitis. J Allergy Clin Immunol 2012;129:1216